This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
NICE has also produced technology appraisal guidance on disease-modifying treatments for multiple sclerosis, listed on NICE’s webpage on multiple sclerosis.
This guideline includes new and updated recommendations on:
It also includes recommendations on:
- modifiable risk factors for relapse or progression
- comprehensive review
- managing relapses and exacerbations
- other treatments
Who is it for?
- Healthcare professionals
- Social care practitioners
- Commissioners and providers
- People with multiple sclerosis and their families and carers
Guideline development process
This guideline updates and replaces NICE guideline CG186 (October 2014) and NICE evidence summary ESUOM9.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.